Please use this identifier to cite or link to this item:
Title: FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors
Authors: Ho, I.A 
Ng, W.H 
Lam, P.Y 
Issue Date: 2010
Citation: Ho, I.A, Ng, W.H, Lam, P.Y (2010). FasL and FADD delivery by a glioma-specific and cell cycle-dependent HSV-1 amplicon virus enhanced apoptosis in primary human brain tumors. Molecular Cancer 9 : 270. ScholarBank@NUS Repository.
Rights: Attribution 4.0 International
Abstract: Background: Glioblastoma multiforme is the most malignant cancer of the brain and is notoriously difficult to treat due to the highly proliferative and infiltrative nature of the cells. Herein, we explored the combination treatment of pre-established human glioma xenograft using multiple therapeutic genes whereby the gene expression is regulated by both cell-type and cell cycle-dependent transcriptional regulatory mechanism conferred by recombinant HSV-1 amplicon vectors.Results: We demonstrated for the first time that Ki67-positive proliferating primary human glioma cells cultured from biopsy samples were effectively induced into cell death by the dual-specific function of the pG8-FasL amplicon vectors. These vectors were relatively stable and exhibited minimal cytotoxicity in vivo. Intracranial implantation of pre-transduced glioma cells resulted in better survival outcome when compared with viral vectors inoculated one week post-implantation of tumor cells, indicating that therapeutic efficacy is dependent on the viral spread and mode of viral vectors administration. We further showed that pG8-FasL amplicon vectors are functional in the presence of commonly used treatment regimens for human brain cancer. In fact, the combined therapies of pG8-FasL and pG8-FADD in the presence of temozolomide significantly improved the survival of mice bearing intracranial high-grade gliomas.Conclusion: Taken together, our results showed that the glioma-specific and cell cycle-dependent HSV-1 amplicon vector is potentially useful as an adjuvant therapy to complement the current gene therapy strategy for gliomas. © 2010 Ho et al; licensee BioMed Central Ltd.
Source Title: Molecular Cancer
ISSN: 14764598
DOI: 10.1186/1476-4598-9-270
Rights: Attribution 4.0 International
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1186_1476-4598-9-270.pdf2.95 MBAdobe PDF




checked on Jul 25, 2021

Page view(s)

checked on Jul 22, 2021

Google ScholarTM



This item is licensed under a Creative Commons License Creative Commons